These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29484273)

  • 41. Molecular, Electrophysiological, and Ultrasonographic Differences in Selected Immune-Mediated Neuropathies with Therapeutic Implications.
    Dziadkowiak E; Nowakowska-Kotas M; Rałowska-Gmoch W; Budrewicz S; Koszewicz M
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298132
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasmacytosis is a common immune signature in patients with MMN and CIDP and responds to treatment with IVIg.
    Korporal-Kuhnke M; Haas J; Schwarz A; Jarius S; Wildemann B
    J Neuroimmunol; 2015 Jan; 278():60-8. PubMed ID: 25595253
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Systematic reviews of treatment for chronic inflammatory demyelinating neuropathy.
    Hughes RA
    Rev Neurol (Paris); 2002 Dec; 158(12 Pt 2):S32-6. PubMed ID: 12690659
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins.
    Ritter C; Bobylev I; Lehmann HC
    J Neuroinflammation; 2015 Aug; 12():148. PubMed ID: 26268846
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Subcutaneous immunoglobulin therapy for inflammatory neuropathy: current evidence base and future prospects.
    Rajabally YA
    J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):631-7. PubMed ID: 24124042
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.
    Cornblath DR; Hartung HP; Katzberg HD; Merkies ISJ; van Doorn PA
    J Peripher Nerv Syst; 2018 Jun; 23(2):108-114. PubMed ID: 29603842
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immune-Mediated Neuropathies.
    Gwathmey KG; Smith AG
    Neurol Clin; 2020 Aug; 38(3):711-735. PubMed ID: 32703478
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of chronic inflammatory demyelinating polyneuropathy.
    Comi G; Roveri L
    Ital J Neurol Sci; 1998 Oct; 19(5):261-9. PubMed ID: 10933445
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte FcgammaRII expression in patients with chronic inflammatory neuropathies.
    Créange A; Gregson NA; Hughes RA
    J Neuroimmunol; 2003 Feb; 135(1-2):91-5. PubMed ID: 12576228
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
    van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
    Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.
    Eftimov F; Winer JB; Vermeulen M; de Haan R; van Schaik IN
    Cochrane Database Syst Rev; 2013 Dec; (12):CD001797. PubMed ID: 24379104
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.
    Igarashi A; Kanegane H; Kobayashi M; Miyawaki T; Tsutani K
    Clin Ther; 2014 Nov; 36(11):1616-24. PubMed ID: 25236916
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [IgIV at home:experience of a center--economic aspects].
    Hachulla E
    Rev Med Interne; 2007 May; 28 Spec No. 1():7-10. PubMed ID: 17768832
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New insights into the management of chronic inflammatory demyelinating polyradiculoneuropathy.
    Rajabally YA; Blomkwist-Markens PH; Katzberg HD
    Neurodegener Dis Manag; 2015; 5(3):257-68. PubMed ID: 26107324
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan.
    Nobile-Orazio E; Gallia F; Terenghi F; Bianco M
    Expert Rev Neurother; 2017 Aug; 17(8):755-765. PubMed ID: 28597710
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical Features of Lewis-Sumner Syndrome: Can Trauma Precipitate Symptoms?
    Hughes IMW; Goodridge AE
    Can J Neurol Sci; 2019 Mar; 46(2):243-247. PubMed ID: 30724154
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of immune neuropathies.
    Van Doorn PA; Garssen MP
    Curr Opin Neurol; 2002 Oct; 15(5):623-31. PubMed ID: 12352007
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature.
    Darabi K; Abdel-Wahab O; Dzik WH
    Transfusion; 2006 May; 46(5):741-53. PubMed ID: 16686841
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial.
    Nobile-Orazio E; Cocito D; Jann S; Uncini A; Beghi E; Messina P; Antonini G; Fazio R; Gallia F; Schenone A; Francia A; Pareyson D; Santoro L; Tamburin S; Macchia R; Cavaletti G; Giannini F; Sabatelli M;
    Lancet Neurol; 2012 Jun; 11(6):493-502. PubMed ID: 22578914
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years.
    Gentile L; Mazzeo A; Russo M; Arimatea I; Vita G; Toscano A
    Sci Rep; 2020 May; 10(1):7910. PubMed ID: 32404895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.